Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
Subscribe To Our Newsletter & Stay Updated
